Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pmv Pharmaceuticals Inc (PMVP)

Pmv Pharmaceuticals Inc (PMVP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,983
  • Shares Outstanding, K 53,212
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,710 K
  • EBIT $ -92 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.53

Options Overview Details

View History
  • Implied Volatility 277.99% (+66.47%)
  • Historical Volatility 50.22%
  • IV Percentile 70%
  • IV Rank 19.31%
  • IV High 820.08% on 10/17/25
  • IV Low 148.26% on 10/24/25
  • Expected Move (DTE 18) 1.1475 (94.06%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,017
  • Open Int (30-Day) 2,042
  • Expected Range 0.0725 to 2.3675

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.44
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +9.91%
on 12/17/25
1.3499 -9.62%
on 12/01/25
-0.1000 (-7.58%)
since 11/28/25
3-Month
1.1100 +9.91%
on 12/17/25
1.6700 -26.95%
on 10/24/25
-0.2300 (-15.86%)
since 09/29/25
52-Week
0.8100 +50.62%
on 05/16/25
1.8400 -33.70%
on 09/10/25
-0.2800 (-18.67%)
since 12/27/24

Most Recent Stories

More News
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular...

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics  Confirmed responses observed in eight tumor types spanning...

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring...

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and...

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

PMVP : 1.2200 (-1.61%)
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

PMVP : 1.2200 (-1.61%)

Business Summary

PMV Pharmaceuticals Inc.is a precision oncology company. It engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. PMV Pharmaceuticals Inc.is headquartered in Cranbury, New Jersey.

See More

Key Turning Points

3rd Resistance Point 1.2867
2nd Resistance Point 1.2733
1st Resistance Point 1.2467
Last Price 1.2200
1st Support Level 1.2067
2nd Support Level 1.1933
3rd Support Level 1.1667

See More

52-Week High 1.8400
Fibonacci 61.8% 1.4465
Fibonacci 50% 1.3250
Last Price 1.2200
Fibonacci 38.2% 1.2035
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar